Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biperiden. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.82 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.82 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | HRH1 | P35367 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.82 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biperiden SCHEMBL6775788 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL16449751 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL20229362 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL16449749 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL18281119 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL23697535 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL13898507 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL18281117 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL20211718 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 | |
| Biperiden SCHEMBL20229360 | 0.90 | CYP2D6 (1.00) | CYP2D6CHRM2CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-4687886-A1 | METHODS OF DOSING SPINOGENIC COMPOUNDS | Spinogenix, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12486287-B2 | Solid forms of a promoter of spinogenesis | SPINOGENIX, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4620527-A2 | SOLID FORMS OF A PROMOTER OF SPINOGENESIS | Spinogenix, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3917521-B1 | SOLID FORMS OF A PROMOTER OF SPINOGENESIS | SPINOGENIX INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12291797-B2 | Fibronectin type III domain based scaffold compositions, methods and uses | JANSSEN BIOTECH, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119490468-A | Solid forms of acanthogenesis promoting agent | 斯皮诺吉尼克斯公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240423962-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | SPINOGENIX INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-5869097-A | OSMOTIC CAPLET EXIT FOR DELIVERING A PRESELECTED DOSE OF DRUG | ALZA CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5496836-A | Use of famotidine and related compounds in the treatment of movement disorders | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995030416-A1 | THE USE OF FAMOTIDINE AND RELATED COMPOUNDS IN THE TREATMENT OF MOVEMENT DISORDERS | DIROCCO ALESSANDRO (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423962-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | FSCN1, SMN1; SMN2, DCX | CHRM1 3582/4885CYP2D6 4131/4885CHRM2 3588/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CHRM1 1333/4885CYP2D6 462/4885CHRM2 1687/4885 |
| US-12486287-B2 | Solid forms of a promoter of spinogenesis | BMP4, ZFX, RCC1 | CHRM1 3559/4885CYP2D6 3057/4885CHRM2 3585/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CHRM1 1472/4885CYP2D6 485/4885CHRM2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.